Literature DB >> 11224527

PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Y Latchman1, C R Wood, T Chernova, D Chaudhary, M Borde, I Chernova, Y Iwai, A J Long, J A Brown, R Nunes, E A Greenfield, K Bourque, V A Boussiotis, L L Carter, B M Carreno, N Malenkovich, H Nishimura, T Okazaki, T Honjo, A H Sharpe, G J Freeman.   

Abstract

Programmed death I (PD-I)-deficient mice develop a variety of autoimmune-like diseases, which suggests that this immunoinhibitory receptor plays an important role in tolerance. We identify here PD-1 ligand 2 (PD-L2) as a second ligand for PD-1 and compare the function and expression of PD-L1 and PD-L2. Engagement of PD-1 by PD-L2 dramatically inhibits T cell receptor (TCR)-mediated proliferation and cytokine production by CD4+ T cells. At low antigen concentrations, PD-L2-PD-1 interactions inhibit strong B7-CD28 signals. In contrast, at high antigen concentrations, PD-L2-PD-1 interactions reduce cytokine production but do not inhibit T cell proliferation. PD-L-PD-1 interactions lead to cell cycle arrest in G0/G1 but do not increase cell death. In addition, ligation of PD-1 + TCR leads to rapid phosphorylation of SHP-2, as compared to TCR ligation alone. PD-L expression was up-regulated on antigen-presenting cells by interferon gamma treatment and was also present on some normal tissues and tumor cell lines. Taken together, these studies show overlapping functions of PD-L1 and PD-L2 and indicate a key role for the PD-L-PD-1 pathway in regulatingT cell responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11224527     DOI: 10.1038/85330

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  1011 in total

Review 1.  Activation and inhibition of lymphocytes by costimulation.

Authors:  Kenneth A Frauwirth; Craig B Thompson
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

2.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

Authors:  T Okazaki; A Maeda; H Nishimura; T Kurosaki; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

Review 3.  B cell inhibitory receptors and autoimmunity.

Authors:  Nicholas R Pritchard; Kenneth G C Smith
Journal:  Immunology       Date:  2003-03       Impact factor: 7.397

Review 4.  The immunological synapse.

Authors:  Michael L Dustin
Journal:  Cancer Immunol Res       Date:  2014-11       Impact factor: 11.151

5.  PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A.

Authors:  Nikolaos Patsoukis; Duygu Sari; Vassiliki A Boussiotis
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

6.  Subversion of pulmonary dendritic cell function by paramyxovirus infections.

Authors:  Antonieta Guerrero-Plata; Deepthi Kolli; Chao Hong; Antonella Casola; Roberto P Garofalo
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 7.  A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis.

Authors:  Eleanor A Fallon; Bethany M Biron-Girard; Chun-Shiang Chung; Joanne Lomas-Neira; Daithi S Heffernan; Sean F Monaghan; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2018-02-02       Impact factor: 4.962

8.  Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.

Authors:  Xiaofang Xing; Jianping Guo; Guangyu Ding; Bo Li; Bin Dong; Qin Feng; Shen Li; Jian Zhang; Xiaomin Ying; Xiaojing Cheng; Ting Guo; Hong Du; Ying Hu; Tao Zhou; Xiaohong Wang; Lin Li; Qingda Li; Meng Xie; Liting Li; Xiangyu Gao; Fei Shan; Ziyu Li; Xianzi Wen; Jiping Wang; Jiafu Ji
Journal:  Oncoimmunology       Date:  2017-12-21       Impact factor: 8.110

Review 9.  A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.

Authors:  Caroline E Nunes-Xavier; Javier C Angulo; Rafael Pulido; José I López
Journal:  Curr Urol Rep       Date:  2019-01-15       Impact factor: 3.092

Review 10.  Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors:  Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.